Buchumschlag

From understanding to action: Exploring molecular connections of Down syndrome to Alzheimer's disease for targeted therapeutic approach

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Sonal Sukreet, Michael S. Rafii, Robert A. Rissman
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

The impact of congenital heart disease on the timing of Alzheimer's disease in Down syndrome
von: Julianne G. Clina, et al.
Veröffentlicht: (2026)

Cognitive and functional performance and plasma biomarkers of early Alzheimer's disease in Down syndrome
von: Emily K. Schworer, et al.
Veröffentlicht: (2024)

Application of machine learning to blood‐based biomarkers of Alzheimer's disease in Down syndrome
von: Patrick H. Luckett, et al.
Veröffentlicht: (2026)

Prodromal Alzheimer's disease can affect activities of daily living for adults with Down syndrome
von: Tracy A. Listwan, et al.
Veröffentlicht: (2024)

Examining the propensity and nature of criminal risk behaviours in frontotemporal dementia syndromes and Alzheimer's disease
von: Fiona Kumfor, et al.
Veröffentlicht: (2024)

Association of plasma neurofilament light chain with microstructural white matter changes in Down syndrome
von: Herminia Diana Rosas, et al.
Veröffentlicht: (2024)

A systematic review and meta‐analysis of basal microbiota and cognitive function in Alzheimer's disease: A potential target for treatment or a contributor to disease progression?
von: Ana Maria Jimenez‐García, et al.
Veröffentlicht: (2024)

Plasma p‐tau217 for Alzheimer's disease diagnosis: a memory clinic implementation approach
von: Giorgia Brodini, et al.
Veröffentlicht: (2026)

Bayesian analyses for research on Alzheimer's disease and related disorders—updating one's knowledge
von: Stefan Teipel, et al.
Veröffentlicht: (2025)

Disentangling the genetic underpinnings of neuropsychiatric symptoms in Alzheimer's disease in the Alzheimer's Disease Sequencing Project: Study design and methodology
von: Nicholas R. Ray, et al.
Veröffentlicht: (2024)

Interchangeability of CSF and PET to identify Alzheimer's disease pathology
von: Samantha C. Burnham, et al.
Veröffentlicht: (2026)

Neurofilament light chain concentration mediates the association between regional medial temporal lobe structure and memory in adults with Down syndrome
von: Natalie DiProspero, et al.
Veröffentlicht: (2024)

Association of latent factors of neuroinflammation with Alzheimer's disease pathology and longitudinal cognitive decline
von: Stefan J. Teipel, et al.
Veröffentlicht: (2024)

Divergent effects of age on imaging‐based ATN biomarkers and cognition in Alzheimer's disease
von: Lars Frings, et al.
Veröffentlicht: (2025)

Diagnosing Alzheimer's disease: Which dementia screening test to use in elderly Puerto Ricans with mild cognitive impairment and early Alzheimer's disease?
von: María A. Rodríguez‐Santiago, et al.
Veröffentlicht: (2024)

Aβ oligomers peak in early stages of Alzheimer's disease preceding tau pathology
von: Lara Blömeke, et al.
Veröffentlicht: (2024)

How can Alzheimer's disease blood‐based biomarkers reach clinical practice?
von: Robert Perneczky, et al.
Veröffentlicht: (2025)

Association between BrainAGE and Alzheimer's disease biomarkers
von: Yousaf Abughofah, et al.
Veröffentlicht: (2025)

General practitioners’ perspectives on blood biomarkers for Alzheimer's disease
von: Thomas Claessen, et al.
Veröffentlicht: (2025)

Atrophy signature for alpha‐synuclein copathology in Alzheimer's disease
von: Diana Esteller‐Gauxax, et al.
Veröffentlicht: (2026)

Treating Alzheimer's disease in a person living with HIV
von: David B. Clifford, et al.
Veröffentlicht: (2026)

Diagnostic performance of light reflex pupillometry in Alzheimer's disease
von: Mathias Holsey Gramkow, et al.
Veröffentlicht: (2024)

Brain‐derived tau to measure treatment effect in Alzheimer's disease and frontotemporal dementia
von: Cassandra Marotta, et al.
Veröffentlicht: (2025)

Technology‐based instrumental activities of daily living in persons with Alzheimer's disease and related disorders
von: Jared F. Benge, et al.
Veröffentlicht: (2024)

Cerebrospinal fluid sclerostin levels in the early Alzheimer's disease stages
von: Manuela Dicarlo, et al.
Veröffentlicht: (2026)

Cerebrospinal fluid soluble insulin receptor levels in Alzheimer's disease
von: Peter Thomas, et al.
Veröffentlicht: (2024)

Alzheimer's disease neuropathology and longitudinal change in subjective cognitive complaints
von: Alisa Bannerjee, et al.
Veröffentlicht: (2025)

Longitudinal changes in functional capacity in frontotemporal dementia and Alzheimer's disease
von: David Foxe, et al.
Veröffentlicht: (2024)

Relationship of plasma biomarkers to digital cognitive tests in Alzheimer's disease
von: Sofia Toniolo, et al.
Veröffentlicht: (2024)

Elevated tau in the piriform cortex in Alzheimer's but not Parkinson's disease using PET‐MR
von: Hossein Moein Taghavi, et al.
Veröffentlicht: (2024)

Brain atrophy and clinical diagnosis independently predict default mode network failure across the Alzheimer's disease continuum
von: Mohammed Alghamdi, et al.
Veröffentlicht: (2026)

Caregivers’ attitudes toward blood‐based biomarker testing for Alzheimer's disease
von: Katharina Bolsewig, et al.
Veröffentlicht: (2024)

Poor dream recall associates with Alzheimer's disease biomarkers and dementia risk
von: Darren M. Lipnicki, et al.
Veröffentlicht: (2026)

Real‐world experience with lecanemab therapy for Alzheimer's disease in the Intermountain West
von: Bethany C. Curd, et al.
Veröffentlicht: (2026)

Amyloid accumulation, brain atrophy, and cognitive decline in emergent Alzheimer's disease
von: Ying Xia, et al.
Veröffentlicht: (2025)

Machine learning models of Alzheimer's disease spectrum using blood tests
von: Nicola Walter Falasca, et al.
Veröffentlicht: (2025)

Sensory changes in preclinical, prodromal, and clinical Alzheimer's disease and related dementias
von: Willa D. Brenowitz, et al.
Veröffentlicht: (2026)

Effects of obesity on plasma biomarker and amyloid PET trajectories in Alzheimer's disease
von: Soheil Mohammadi, et al.
Veröffentlicht: (2025)

White matter hyperintensities in Alzheimer's disease in the era of anti‐amyloid therapies
von: Antoine Garnier‐Crussard, et al.
Veröffentlicht: (2026)

Serum biomarkers as prognostic markers for Alzheimer's disease in a clinical setting
von: Steffi De Meyer, et al.
Veröffentlicht: (2025)